Compare Danaher Corporation (DHR) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Nomura Holdings Inc — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while Nomura Holdings Inc trades at $9.59 (market cap $27.55B). The key difference: Danaher Corporation is far larger — about 5.5× Nomura Holdings Inc's market cap, and Nomura Holdings Inc pays the higher dividend (3.4%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Nomura Holdings Inc for 55 Days on average.
| DHR | NMR | |
|---|---|---|
Market Cap | $152.87B | $27.55B |
Volume | 5,228,698 | 782,470 |
Sector | Health | Financials |
52-Week High | $242.05 | $10.86 |
52-Week Low | $161.91 | $6.73 |
Typical Hold Time | 69 Days | 55 Days |
Enterprise Value | $175.08B | $38.54T |
Dividend Yield | 0.74% | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
Nomura Holdings (NMR) trades at $9.54, up 0.1% on the day, with a bearish technical signal but strong fundamental metrics including a P/E of 11.33 and net income margin of 20.4%. Recent earnings show a mix of beats and misses, while cash flow trends indicate significant financing activity. The stock is near its support level of $9, with RSI indicators suggesting potential oversold conditions. Zacks Research highlighted NMR as a strong buy for momentum and value in September 2026, citing recent price strength.
The outlook for NMR is cautiously optimistic, supported by solid profitability and valuation, but tempered by bearish technicals and inconsistent earnings performance. Key risks include high debt levels and macroeconomic sensitivity, while analyst sentiment leans hold. Upside potential exists if earnings stabilize and technical support holds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
